{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:12Z","timestamp":1784612532755,"version":"3.55.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The study aimed to establish a population pharmacokinetic (PPK) model of tacrolimus for Chinese patients with nephrotic syndrome using the patient's genotype and Wuzhi capsule dosage as the main test factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Ninety-six adult patients with nephrotic syndrome, who were receiving tacrolimus treatment, were enrolled. A nonlinear mixed-effects model was used to determine the influencing factors of interindividual tacrolimus metabolism variation and establish a PPK model. To optimize the tacrolimus dosage, 10,000 Monte Carlo simulations were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The 1-chamber model of first-order absorption and elimination was the most suitable model for the data in this study. The typical population tacrolimus clearance (<jats:italic toggle=\"yes\">CL\/F<\/jats:italic>) value was 16.9 L\/h. The percent relative standard error (RSE%) of <jats:italic toggle=\"yes\">CL\/F<\/jats:italic> was 12%. Increased Wuzhi capsule and albumin doses both decreased the tacrolimus <jats:italic toggle=\"yes\">CL\/F<\/jats:italic>. In <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic> homozygous mutation carriers, the <jats:italic toggle=\"yes\">CL\/F<\/jats:italic> was 39% lower than that of carriers of the wild-type and heterozygous mutation. The tacrolimus <jats:italic toggle=\"yes\">CL\/F<\/jats:italic> in patients who were coadministered glucocorticoids was 1.23-fold higher than that of the control. According to the patient genotype and combined use of glucocorticoids, 26 combinations of Wuzhi capsule and tacrolimus doses were matched. The Monte Carlo simulation identified the most suitable combination scheme.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>An improved tacrolimus PPK model for patients with nephrotic syndrome was established, and the most suitable combination of Wuzhi capsule and tacrolimus doses was identified, thus, facilitating the selection of a more economical and safe administration regimen.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001008","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T21:13:05Z","timestamp":1656364385000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Tacrolimus Population Pharmacokinetic Model in Adult Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo Simulations"],"prefix":"10.1097","volume":"44","author":[{"given":"Minghao","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University ; and"},{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University ; and"},{"name":"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-3337","authenticated-orcid":false,"given":"Mingming","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0272-6386(12)80369-6","article-title":"Extrarenal complications of the nephrotic syndrome","volume":"23","author":"Raymond","year":"1994","journal-title":"Am J Kidney Dis."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/bcp.13605","article-title":"Population pharmacokinetics of tacrolimus in children with nephrotic syndrome","volume":"84","author":"Hao","year":"2018","journal-title":"Br J Clin Pharmacol."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","article-title":"Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of glomerulonephritis in adults","volume":"63","author":"Samuel","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1399-0012.2005.00370.x","article-title":"Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation","volume":"19","author":"Zhang","year":"2005","journal-title":"Clin Transpl."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/FTD.0b013e31824a67eb","article-title":"The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients","volume":"34","author":"Zhang","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11318080-000000000-00000","article-title":"Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients","volume":"48","author":"Benkali","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jcph.1325","article-title":"Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities","volume":"59","author":"Campagne","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000331856","article-title":"Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers","volume":"88","author":"Xue","year":"2011","journal-title":"Pharmacology"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1067\/mcp.2002.129304","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant recipients","volume":"72","author":"Staatz","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R12-20250603","first-page":"257","article-title":"Pharmacokinetic interaction between glucocorticoids and tacrolimus after renal transplantation","volume":"28","author":"Yang","year":"2019","journal-title":"J Pharm Sci"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/jcpt.12828","article-title":"Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: a retrospective study","volume":"44","author":"Wang","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1111\/j.1600-6143.2012.04232.x","article-title":"Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs","volume":"12","author":"Jacobson","year":"2012","journal-title":"Am J Transpl."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s002280100331","article-title":"Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation","volume":"57","author":"Fukatsu","year":"2001","journal-title":"Eur J Clin Pharmacol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/sj.bmt.1703224","article-title":"Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients","volume":"28","author":"Jacobson","year":"2001","journal-title":"Bone Marrow Transpl."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids","volume":"56","author":"Hesselink","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jcpt.12523","article-title":"Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients","volume":"42","author":"Zhang","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","article-title":"Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis","volume":"23","author":"Zuo","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1124\/dmd.112.050302","article-title":"Effects of traditional Chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats","volume":"41","author":"Wei","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/dmd.113.053892","article-title":"In vivo to in vitro effects of six bioactive lignans of Wuzhi Tablet (Schisandra Sphenanthera Extract) on the CYP3A\/P-glycoprotein-mediated absorption and metabolism of tacrolimus","volume":"42","author":"Qin","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11095-019-2579-6","article-title":"Dosage optimization based on population pharmacokinetic analysis of tacrolimus in Chinese patients with nephrotic syndrome","volume":"36","author":"Lu","year":"2019","journal-title":"Pharm Res."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/pgs-2018-0116","article-title":"Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach","volume":"20","author":"Han","year":"2019","journal-title":"Pharmacogenomics"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2007.02922.x","article-title":"Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers","volume":"64","author":"Xin","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s11255-014-0801-3","article-title":"Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics","volume":"46","author":"Sun","year":"2014","journal-title":"Int Urol Nephrol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc Natl Acad Sci U S A."},{"key":"R27-20250603","first-page":"4023","article-title":"Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models","volume":"17","author":"Wang","year":"2019","journal-title":"Exp Ther Med."},{"key":"R28-20250603","first-page":"178","article-title":"Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients","volume":"50","author":"Wang","year":"2019","journal-title":"Xenobiotica"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jcpt.12707","article-title":"Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study","volume":"43","author":"Wang","year":"2018","journal-title":"J Clin Pharm Ther."},{"key":"R30-20250603","first-page":"1195","article-title":"Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients","volume":"38","author":"Chen","year":"2017","journal-title":"Acta Pharmacolo"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","article-title":"Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients","volume":"45","author":"Sam","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R32-20250603","first-page":"713650","article-title":"The population pharmacokinetic models of tacrolimus in Chinese adult liver transplantation patients","volume":"2014","author":"Zhu","year":"2014","journal-title":"J Pharm."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/jcpt.13072","article-title":"Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule","volume":"45","author":"Chen","year":"2020","journal-title":"J Clin Pharm Ther."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2217\/pgs-2017-0139","article-title":"Tacrolimus population pharmacokinetic models according to CYP3A5\/CYP3A4\/POR genotypes in Chinese Han renal transplant patients","volume":"19","author":"Zhu","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.phymed.2012.11.008","article-title":"Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus","volume":"20","author":"Qin","year":"2013","journal-title":"Phytomedicine"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int J Pharm."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","article-title":"Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506)","volume":"389","author":"Qin","year":"2010","journal-title":"Int J Pharm."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00280-005-0133-1","article-title":"Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein","volume":"58","author":"Pan","year":"2006","journal-title":"Cancer Chemother Pharmacol."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1124\/dmd.104.000646","article-title":"Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract","volume":"32","author":"Iwata","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1124\/jpet.105.094342","article-title":"Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate Pregnane X receptor and increase Warfarin clearance in rats","volume":"316","author":"Mu","year":"2006","journal-title":"J Pharm Exp Ther."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1124\/dmd.109.027433","article-title":"Effects of short-term and long-term pretreatment of Schisandra Lignans on regulating hepatic and intestinal CYP3A in rats","volume":"37","author":"Lai","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0041-1345(98)00234-6","article-title":"Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation","volume":"30","author":"Undre","year":"1998","journal-title":"Transpl Proc"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.1K62B","article-title":"Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction","volume":"42","author":"Lam","year":"2008","journal-title":"Ann Pharmacother."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/00498250110102674","article-title":"Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man","volume":"32","author":"Gibson","year":"2008","journal-title":"Xenobiotica"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","article-title":"Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin","volume":"276","author":"Geick","year":"2001","journal-title":"J Biol Chem."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","article-title":"Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation","volume":"18","author":"Anglicheau","year":"2003","journal-title":"Nephrol Dial Transpl."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e31826c3985","article-title":"NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK Viremia in adult kidney transplantation","volume":"94","author":"Barraclough","year":"2012","journal-title":"Transplantation"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/01.ftd.0000170029.36573.a0","article-title":"Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients","volume":"27","author":"Zahir","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.13838","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients","volume":"85","author":"Andrews","year":"2019","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:11:39Z","timestamp":1748970699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001008","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2021-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}